ClinicalTrials.gg
RecruitingNCT07843225IMFCUpdated Oct 14, 2026

Standard Closure vs. Integrated Mesh-Fascial Closure (IMFC) for Incisional Hernia Repair

An interventional study of Integrated Mesh-Fascial Closure and Standard Fascial Closure with Mesh in Incisional Hernia Repair and Ventral Incisional Hernia, sponsored by Hospital Zonal General De Agudos Mario V Larrain. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Hospital Zonal General De Agudos Mario V Larrain · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 14, 2026Primary outcomes revisedStart date moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study compares two surgical techniques for closing the abdominal wall in adult patients who have an incisional hernia (a weakness or opening in a previous surgical incision) or who require prophylactic mesh placement during a laparotomy.

In one group, the abdominal wall is closed using the standard technique, in which a polypropylene mesh is fixed independently from the fascial suture. In the other group, Integrated Mesh-Fascial Closure (IMFC) is used, a standardized execution of the technique of mesh incorporation into the fascial closure described by Jamal et al (Hernia, 2013).

The choice of technique is made by the patient after receiving information about both options and providing informed consent. Participants will be followed clinically and with imaging for 18 to 24 months to evaluate the safety, technical feasibility, and reproducibility of the IMFC technique, and to determine the incidence of hernia recurrence in both groups.

Read the detailed description

Incisional hernia is one of the most frequent complications of abdominal surgery, with a reported incidence of 10-20% after laparotomy, and recurrence rates after mesh repair reaching 20-30% in long-term follow-up. In conventional techniques, primary fascial closure and mesh fixation are performed as two mechanically independent steps, concentrating tension on the suture line during the acute postoperative period.

The Integrated Mesh-Fascial Closure (IMFC) technique integrates a macroporous polypropylene mesh within a continuous fascial suture line (pattern: mesh → right fascial edge → left fascial edge → mesh), aiming to distribute tensile load simultaneously between the fascia and the prosthesis, potentially reducing the incidence of hernia recurrence compared to standard closure. The principle of incorporating the mesh into the fascial closure was described by Jamal et al in a retrospective series of 72 patients. IMFC standardizes its execution (suture material, 5-mm bites in mesh and fascia, anchoring of the suture line in healthy aponeurosis, and optional minimal peripheral fixation) and evaluates it prospectively against standard closure.

This is a prospective, comparative, quasi-experimental (non-randomized) study conducted at a single center (Hospital Zonal General de Agudos "Dr. Mario V. Larrain," Berisso, Argentina). Eligible patients choose, after informed consent, between standard mesh closure (Group A) or IMFC (Group B). Both groups follow the same clinical and imaging follow-up schedule (days 7, 15, 30; months 2, 6, 12, 18; and a final visit between 18 and 24 months).

The study is designed as an initial, hypothesis-generating comparison of safety, technical feasibility, and reproducibility across surgeons, intended to support a future randomized trial.

02

Conditions studied

  • Incisional Hernia Repair
  • Ventral Incisional Hernia

Keywords

  • incisional hernia
  • ventral hernia
  • surgical mesh
  • fascial closure
  • abdominal wall surgery
  • hernia recurrence
  • IMFC
03

In context

Incisional Hernia

212 studies on the registry are indexed under Incisional Hernia; 58 are open to participants now.

This study's planned enrollment of 60 is below the median of 110 across 130 interventional studies indexed under Incisional Hernia.

Browse Incisional Hernia studies →

Lead sponsor

This is the only study on the registry with Hospital Zonal General De Agudos Mario V Larrain as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults older than 18 years of age
  • Patients with incisional (ventral) hernia
  • Patients with recurrent incisional hernia
  • Incisional hernias with a diameter greater than 4 cm
  • Patients undergoing laparotomy with an indication for prophylactic mesh placement

Exclusion criteria

Exclusion Criteria:

  • Active surgical site infection
  • Overt abdominal contamination
  • Tissue necrosis or inability to achieve primary fascial closure
  • Non-correctable loss of domain
  • Pregnant women or women of planning pregnancy or not using during the follow-up period
  • Patients belonging to vulnerable populations, in accordance with Law 15.462 and applicable ethical guidelines
  • Active oncologic disease (patients with a cured oncologic history may be included)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Standard Mesh Closure

    Conventional fascial closure using a macroporous polypropylene mesh fixed independently from the closure suture

    Procedure: Standard Fascial Closure with Mesh

  • Experimental
    Integrated Mesh-Fascial Closure - IMFC

    Fascial closure using the Integrated Mesh-Fascial Closure (IMFC) technique: the mesh is incorporated within the trajectory of a single continuous fascial suture (pattern: mesh → right fascial edge → left fascial edge → mesh

    Procedure: Integrated Mesh-Fascial Closure

Interventions

  • ProcedureIntegrated Mesh-Fascial Closure

    Same materials integrated into a single continuous suture line using the IMFC technique.

  • ProcedureStandard Fascial Closure with Mesh

    Macroporous polypropylene mesh (FILAPROP™/MERIGROW™) plus non-absorbable polypropylene suture, placed using the conventional (independent) technique.

06

What researchers measure

Primary outcomes

  1. Recurrence rate of incisional hernia

    Proportion of participants with hernia recurrence, assessed by clinical physical examination and abdominal wall ultrasound, performed in all participants at 6 months and at the final visit (18-24 months). All ultrasound evaluations performed by the same sonographer throughout the study; the sonographer is aware of study participation but blinded to the specific surgical technique (IMFC vs. standard closure) received by each participant.

    Time frame: 18-24 months (final follow-up visit)

  2. Rate of Major Intraoperative and Postoperative Complications

    Proportion of participants experiencing a serious adverse event (SAE), defined per ICH E6(R3) as death, a life-threatening event, hospitalization or prolongation of hospitalization, persistent or significant disability, or an unplanned surgical reintervention. Postoperative complications additionally graded using the Clavien-Dindo classification system (Grade I-V) to assess severity.

    Time frame: Throughout study participation (up to 24 months)

Secondary outcomes

  1. Operative time and fascial closure time

    Total operative time (from skin incision to skin closure) and fascial closure time (from start to completion of the mesh-fascial suture line), both measured in minutes and recorded intraoperatively by the surgical team using the operating room clock.

    Time frame: Intraoperative (during the surgical procedure)

  2. Postoperative Pain Assessed by the 0-10 Numeric Pain Rating Scale (NRS-11)

    Self-reported postoperative pain intensity measured using the 11-point Numeric Pain Rating Scale (NRS-11), an unabbreviated verbally- or visually-administered numeric scale ranging from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst pain imaginable." Higher scores indicate worse (more severe) pain. Assessed at rest.

    Time frame: Postoperative days 7, 15, and 30

  3. Rate of Early Postoperative Complications (Infection, Seroma, Dehiscence, Hematoma)

    Proportion of participants with surgical site infection, seroma, wound dehiscence, or hematoma, identified by clinical examination at scheduled postoperative visits (days 7, 15, and 30) and graded according to the Clavien-Dindo classification.

    Time frame: Up to 30 days postoperative

  4. Total Direct Hospital Costs (ARS) Associated with Complications or Reoperations

    Total direct hospital costs, expressed in Argentine pesos (ARS), attributable to management of complications or unplanned reoperations, extracted from institutional administrative and billing records. Exploratory outcome; not powered for formal statistical comparison between groups.

    Time frame: Up to 24 months (exploratory)

07

Study locations

1 of 1 sites recruiting
  • Hospital Zonal General de Agudos "Dr. Mario V. Larrain
    Berisso, Buenos Aires 1923, Argentina
    Recruiting
    • Facundo B Mattano, MD · Contactmattanofacundo@outlook.com · +54 9 2216117976
    • Emiliano D Gargiulo, MD · Contact+54 9 221 5371371
08

References and documents

Publications

  • Jamal K, Ratnasingham K, Shaunak S, Ravindran K, Nehra D. A novel technique for modified onlay incisional hernia repair with mesh incorporation into the fascial defect: a method for addressing suture line failure. Hernia. 2015 Jun;19(3):473-7. doi: 10.1007/s10029-013-1195-3. Epub 2013 Dec 19. PubMed 24352638 ↗

Individual participant data

Plan to share: No

09

Updates

3 registry updates since Sep 25, 2026
Start date
Sep 18, 2026→Sep 28, 2026 (actual)
Sep 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionRecurrence rate of incisional hernia: how it is measured was reworded
Oct 14, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 3 updates
  1. Oct 14, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionRecurrence rate of incisional hernia: how it is measured was reworded
    + 4 other changes: verification date, description, design details and references
  2. Sep 30, 2026
    Start date Sep 18, 2026→Sep 28, 2026 (now actual)
  3. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843225
Lead sponsor
Hospital Zonal General De Agudos Mario V Larrain
Responsible party
Bovino Mattano Facundo (Surgeon (General Surgery), Urologist, Principal Investigator, Hospital Zonal General De Agudos Mario V Larrain) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 28, 2026
Primary completion
Oct 15, 2030 (estimated)
Completion
Oct 15, 2032 (estimated)
Last update
Oct 14, 2026

Study contacts

Facundo B Mattano, MD
Contact
mattanofacundo@outlook.com
+54 9 221 611-7976
Emiliano D Gargiulo, MD
Contact
+54 2215371371
Facundo B Mattano, MD
principal investigator · Hospital Zonal General de Agudos "Dr. Mario V. Larrain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion